Response to Comments: Botulinum Toxin Type A & Type B (DL34635)

This document (A58907) is a response to comments regarding Draft LCD DL34635 and does not itself state coverage indications, limitations, documentation requirements, or frequency limits for Botulinum Toxin Type A or B. For actionable coverage criteria, limitations, required documentation, and frequency limits, consult the final Local Coverage Determination DL34635 and related policy documents; manual review of DL34635 is required.

"No coverage indications are stated in this document; it is a response to comments. Refer to Local Coverage Determination DL34635 for complete covered indications for Botulinum Toxin Type A & B."

Sign up to see full coverage criteria, indications, and limitations.